José Manuel Puerta

1.4k total citations · 1 hit paper
17 papers, 876 citations indexed

About

José Manuel Puerta is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, José Manuel Puerta has authored 17 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Genetics and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in José Manuel Puerta's work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). José Manuel Puerta is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chemotherapy-induced cardiotoxicity and mitigation (4 papers). José Manuel Puerta collaborates with scholars based in Spain. José Manuel Puerta's co-authors include Concepción Ruíz, Rebeca Illescas‐Montes, Víctor J. Costela‐Ruiz, Lucía Melguizo‐Rodríguez, Manuel Jurado, Antonio Romero, María‐José Sánchez, Juan Sáinz, Rafael Ríos and Elisa López‐Fernández and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

José Manuel Puerta

15 papers receiving 857 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

2020 802 citations Víctor J. Costela‐Ruiz, Rebeca Illescas‐Montes et al. Cytokine & Growth Factor Reviews profile →

Peers

Countries citing papers authored by José Manuel Puerta

Since Specialization

Citations

This map shows the geographic impact of José Manuel Puerta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Manuel Puerta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Manuel Puerta more than expected).

Fields of papers citing papers by José Manuel Puerta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Manuel Puerta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Manuel Puerta. The network helps show where José Manuel Puerta may publish in the future.

Co-authorship network of co-authors of José Manuel Puerta

This figure shows the co-authorship network connecting the top 25 collaborators of José Manuel Puerta. A scholar is included among the top collaborators of José Manuel Puerta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Manuel Puerta. José Manuel Puerta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Data Model for the Comprehensive Management of Biobanks and Its Contribution to Personalized Medicine 2024 ·Journal of Personalized Medicine ·(unknown), Purificación Catalina, (unknown), (unknown), Juan David Rejón, (unknown), José Manuel Puerta, Rocío Aguilar‐Quesada	2
2	Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era 2023 ·Pharmaceutics ·(unknown), (unknown), Carolina Alarcón-Payer, (unknown), (unknown), José Manuel Puerta, (unknown)	2
3	A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia 2023 ·Pharmaceutics ·(unknown), (unknown), Carolina Alarcón-Payer, (unknown), José Manuel Puerta	1
4	Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain 2023 ·Haematologica ·(unknown), (unknown), (unknown), José Manuel Puerta	2
5	Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation 2023 ·Scientific Reports ·(unknown), José Manuel Puerta, (unknown), (unknown), (unknown), (unknown), (unknown)	1
6	Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia 2022 ·Journal of Personalized Medicine ·Carolina Alarcón-Payer, (unknown), (unknown), José Manuel Puerta, (unknown)	3
7	Arterial hypertension assessment in a population with chronic myeloid leukemia 2021 ·Scientific Reports ·(unknown), (unknown), José Manuel Puerta, (unknown), (unknown), (unknown)	5
8	Dislipemia en pacientes con enfermedades onco-hematológicas 2021 ·Endocrinología Diabetes y Nutrición ·(unknown), (unknown), (unknown), José Manuel Puerta, (unknown), (unknown)	1
9	SARS-CoV-2 infection: The role of cytokines in COVID-19 disease breakdown → 2020 ·Cytokine & Growth Factor Reviews ·Víctor J. Costela‐Ruiz, Rebeca Illescas‐Montes, José Manuel Puerta, Concepción Ruíz, Lucía Melguizo‐Rodríguez	802
10	Progressive cardiovascular disease in a patient under treatment with nilotinib 2020 ·Clínica e Investigación en Arteriosclerosis (English Edition) ·(unknown), (unknown), (unknown), José Manuel Puerta, (unknown), (unknown)	2
11	Enfermedad cardiovascular progresiva en paciente bajo tratamiento con nilotinib 2019 ·Clínica e Investigación en Arteriosclerosis ·(unknown), (unknown), (unknown), José Manuel Puerta, (unknown), (unknown)	1
12	Reactivación del virus varicela-zóster en dos pacientes inmunodeprimidos 2017 ·Medicina Clínica ·(unknown), José Manuel Puerta, (unknown), Alejandro Molina‐Leyva	0
13	A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia 2017 ·PLoS ONE ·Valentín García‐Gutiérrez, María Teresa Gómez‐Casares, José Manuel Puerta, Juan Manuel Alonso‐Domínguez, Santiago Osorio, Juan Carlos Hernández‐Boluda, Rosa Collado, Marı́a José Ramı́rez, (unknown), María Luisa Martín, (unknown), Carolina Martínez‐Laperche, Montse Gómez, (unknown), (unknown), Alicia Rodríguez, (unknown), Juan Luis Steegmann, Antonio Jiménez‐Velasco, (unknown)	4
14	Early mortality in multiple myeloma: the time‐dependent impact of comorbidity: A population‐based study in 621 real‐life patients 2016 ·American Journal of Hematology ·Rafael Ríos, Juan Sáinz, Joaquín Martínez‐López, José Manuel Puerta, D.Y.L. Chang, Teresa Rodríguez-Blanco, Pilar Carrasco‐Garrido, (unknown), Antonio Romero, (unknown), Elisa López‐Fernández, (unknown), María‐José Sánchez, José Juan Jiménez‐Moleón, Manuel Jurado, Juan José Lahuerta	28
15	Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution 2015 ·Cancer Epidemiology ·Rafael Ríos, María‐José Sánchez, José Manuel Puerta, Juan Sáinz, D.Y.L. Chang, Teresa Rodríguez, Pilar Garrido, (unknown), Pilar Navarro, (unknown), Antonio Romero, Pilar Carrasco‐Garrido, (unknown), Carolina Alarcón-Payer, Elisa López‐Fernández, (unknown), José Juan Jiménez‐Moleón, Miguel Ángel Calleja‐Hernández, Manuel Jurado	20
16	Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method 2015 ·Blood ·Valentín García‐Gutiérrez, María Teresa Gómez‐Casares, (unknown), (unknown), Santiago Osorio, Juan Carlos Hernández‐Boluda, José Manuel Puerta, Rosa Collado, Marı́a José Ramı́rez, (unknown), (unknown), (unknown), Carolina Martínez‐Laperche, (unknown), Montse Gómez, (unknown), Alicia Rodríguez, Concepción Ruíz, Juan Luis Steegmann	1
17	Multiple Myeloma with Prior Precursor Disease Shows Better Outcome 2015 ·Blood ·Rafael Ríos, (unknown), Manuel Jurado, José Manuel Puerta, (unknown), (unknown), (unknown), (unknown), (unknown), Teresa Morales‐Ruíz, José Juan Jiménez‐Moleón, María‐José Sánchez	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact